Takflur comes with an unique formulation that includes both Flurbiprofen and hydroxyl-propyl-methyl-cellulose that prevents mydriasis and inflammation while the other lubricates the cornea.

Flurbiprofen is a member of the phenylalkanoic acid derivative family of non-steroidal anti-inflammatory drugs (NSAIDs) used to treat the inflammation and pain.

Takflur inhibits the activity of both Cyclooxygenase Enzyme (COX-1 & COX-2), and thereby, the synthesis of prostaglandins and Thromboxane. The inhibitory effect of COX 2 is associated with pain relieving activity while COX-1 with anti-inflammatory effect. It also prevents surgically induced miosis in human eyes undergoing cataract extraction. Results from clinical studies indicate that flurbiprofen sodium has no significant effect upon intraocular pressure.

1. Intraoperative miosis
2. Inflammation of the anterior segment of the eye after cataract surgery, after laser trabeculoplasty in the anterior segment of the eye where steroid therapy is not recommended
3. Pseudophakic Cystoid macular edema (CME) postoperatively
4. Ocular pain associated with surgery
5. Post operative dry eye

1. Wound healing may be delayed with the use of Flurbiprofen sodium ophthalmic solution.
2. Should be taken with caution by the patients having bleeding tendency.
3. Hypersensitivity towards any of the component in the ophthalmic solution

Adverse Effect:

1. Eye pain, changes in vision, continued redness or irritation of the eye.
2. Bleeding in the eye.
3. Redness and swelling in the eye ball.
4. Fibrosis, Miosis, Mydriasis, And Ocular Hyperemia.